Last Updated: September 24, 2026

Ascendis Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ASCENDIS

ASCENDIS has two approved drugs.

There are twenty US patents protecting ASCENDIS drugs.

Summary for Ascendis

US Patents:	20
Tradenames:	2
Ingredients:	2
NDAs:	2
Patent Litigation for Ascendis:	See patent lawsuits for Ascendis
PTAB Cases with Ascendis as petitioner:	See PTAB cases with Ascendis as petitioner

Drugs and US Patents for Ascendis

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-003	Aug 9, 2024		RX	Yes	Yes	11,890,326	⤷ Start Trial	Y	Y		⤷ Start Trial
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-003	Feb 27, 2026		RX	Yes	Yes	11,311,604	⤷ Start Trial	Y	Y		⤷ Start Trial
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-001	Feb 27, 2026		RX	Yes	Yes	11,224,661	⤷ Start Trial	Y	Y		⤷ Start Trial
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	Yes	11,890,326	⤷ Start Trial	Y	Y		⤷ Start Trial
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-002	Aug 9, 2024		RX	Yes	Yes	12,453,778	⤷ Start Trial				⤷ Start Trial
Ascendis	YUVIWEL	navepegritide	POWDER;SUBCUTANEOUS	219164-003	Feb 27, 2026		RX	Yes	Yes	12,239,689	⤷ Start Trial				⤷ Start Trial
Ascendis Pharma Bone	YORVIPATH	palopegteriparatide	SOLUTION;SUBCUTANEOUS	216490-001	Aug 9, 2024		RX	Yes	Yes	12,453,778	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for Ascendis Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
South Korea	20190062497	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2017118700	⤷ Start Trial
Croatia	P20231079	⤷ Start Trial
Japan	7434419	⤷ Start Trial
South Korea	102518217	⤷ Start Trial
South Korea	20230170810	⤷ Start Trial
Japan	2022088545	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.